Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 655

Sort by

Sort Order Select

Journal Articles

MCL-1 and BCL-XL: blood brothers

Miriam Erlacher, Verena Labi

Blood (2021) 137 (14): 1850–1851.

https://doi.org/10.1182/blood.2020010569

Published: 2021

Journal Articles

Requirement for antiapoptotic MCL-1 during early erythropoiesis

Meghan E. Turnis, Ewa Kaminska, Kaitlyn H. Smith, Brittany J. Kartchner, Peter Vogel, Jonathan D. Laxton, Richard A. Ashmun, Paul A. Ney, Joseph T. Opferman

Blood (2021) 137 (14): 1945–1958.

https://doi.org/10.1182/blood.2020006916

Published: 2021

Includes: Supplemental data

Journal Articles

IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia

Blood (2020) 136 (13): 1520–1534.

https://doi.org/10.1182/blood.2019002655

Published: 2020

Includes: Supplemental data

Journal Articles

Characterization of Mechanisms of Acquired Venetoclax-Insensitivity in B-Cell Precursor Acute Lymphoblastic Leukemia

Alexandra Niedermayer, MSc, Stefanie Enzenmüller, PhD, Eugen Tausch, Stephan Stilgenbauer, MD, Felix Seyfried, MD, Klaus-Michael Debatin, MD, Lüder Hinrich Meyer, MD

Blood (2019) 134 (Supplement_1): 3954.

https://doi.org/10.1182/blood-2019-126582

Published: 2019

Journal Articles

Rive-CLL: Phase 1 Trial of Rituximab, Idelalisib, and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

John McKay, DO, Taha Al-Juhaishi, MD, Lai Guanhua, MD PhD, Maciej Kmieciak, PhD, Roy Sabo, PhD, Ariel Sindel, DO, Victor Yazbeck, MD

Blood (2019) 134 (Supplement_1): 5482.

https://doi.org/10.1182/blood-2019-126335

Published: 2019

Journal Articles

Ibrutinib Therapy Downregulates Toso, the Fcr for IgM, Expression in CLL Patients

Mariela Sivina, Gordon Duncan, MSc, Takashi Sakamoto, MD PhD, Ekaterina Kim, MS, Alicia Vaca, PhD, Elena Maria Hartmann, MD, Michael J Keating, MBBS, Alessandra Ferrajoli, MD, William G. Wierda, MD PhD, Tak Mak, PhD DSc, Andreas Rosenwald, MD, Jan A. Burger, MD PhD

Blood (2019) 134 (Supplement_1): 5448.

https://doi.org/10.1182/blood-2019-125716

Published: 2019

Journal Articles

Cross-Talk between Cytokine and NF-ĸb Signaling in the CLL Microenvironment Can Affect Sensitivity for Venetoclax

Marco Haselager, MSc, Rachel Thijssen, Arnon P. Kater, Eric Eldering

Blood (2019) 134 (Supplement_1): 5449.

https://doi.org/10.1182/blood-2019-126788

Published: 2019

Journal Articles

First Description of B Cell Maturation Antigen Expression in Light Chain Amyloidosis

Susan Bal, MDMBBS, Allison Sigler, Alexander Chan, MD, David J. Chung, MD PhD, Ahmet Dogan, MD PhD, Sergio A Giralt, MD, Hani Hassoun, MD, Heather J Landau, MD

Blood (2019) 134 (Supplement_1): 5452.

https://doi.org/10.1182/blood-2019-127332

Published: 2019

Journal Articles

The Effect of Apoptosis Inhibitor Blockade Agents on the Third Generation CD19 CAR T Cells

Mingya Yang, MD, Lei Wang, MD, Ming Ni, Maria-Luisa Schubert, MD, Brigitte Neuber, Angela Hückelhoven-Krauss, Ruben A. Gößmann, Christian Kleist, Volker Eckstein, Carsten Müller-Tidow, MD, Peter Dreger, Michael Schmitt, MD, Anita Schmitt, MD

Blood (2019) 134 (Supplement_1): 5620.

https://doi.org/10.1182/blood-2019-125622

Published: 2019

Journal Articles

Targeting CD38 high Acute Myeloid Leukaemia with "Affinity Optimized" Chimeric Antigen Receptor and Membrane Bound TRAIL Expressing Natural Killer Cells

Emma Nolan, BSc, Arwen Stikvoort, PhD, Mark Gurney, MD, Nutsa Burduli, BSc, Lucy Kirkham-McCarthy, MSc, John Daly, MSc, Niels W. C. J. Van De Donk, Tuna Mutis, MD PhD, Subhashis Sarkar, PhD, Michael E O'Dwyer, MD

Blood (2019) 134 (Supplement_1): 5536.

https://doi.org/10.1182/blood-2019-128605

Published: 2019

Journal Articles

Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL

Shanye Yin, PhD, Salma Parvin, PhD, Elisa Ten Hacken, PhD, Rebecca Valentin, MD, Heather Joyal, Laura Z. Rassenti, PhD, Emanuela M. Ghia, PhD, Thomas J. Kipps, MD PhD, Donna S Neuberg, ScD, Lili Wang, MD PhD, Matthew S. Davids, MD, Ruben D. Carrasco, MD PhD, Anthony G. Letai, MD PhD, Catherine J. Wu, MD

Blood (2019) 134 (Supplement_1): 4281.

https://doi.org/10.1182/blood-2019-127293

Published: 2019

Journal Articles

Identification of a New Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia and Studies on Its Mechanism of Action

Kinjal Shah, MS, Julhash U. Kazi, PhD

Blood (2019) 134 (Supplement_1): 2752.

https://doi.org/10.1182/blood-2019-129823

Published: 2019

Journal Articles

A Novel BCL-2/BCL-Xl Dual Inhibitor Overcomes Ibrutinib-Resistance Conferred By the Upregulation of Integrin Pathway and BCL-Xl

Jing Deng, PhD, Tingting Mao, MS, Xiaojing Huang, PhD, Li Rui, Guangfeng Wang, PhD, Douglas D. Fang, MD PhD, Dajun Yang, MD PhD, Yifan Zhai, MD PhD

Blood (2019) 134 (Supplement_1): 2573.

https://doi.org/10.1182/blood-2019-128708

Published: 2019

Journal Articles

The Splicing Modulator GEX1A Exhibits Potent Anti-Leukemic Activity Both in Vitro and In Vivo through Inducing an MCL1 Splice-Switch in Pre-Clinical Models of Acute Myeloid Leukemia

Mark Sellin, Ryan Mack, Matthew C. Rhodes, Lei Zhang, PhD, Wei Wei, Peter Breslin, PhD, Stephanie Berg, DO, Suming Huang, PhD, Richard Taylor, PhD, Jiwang Zhang, MD

Blood (2019) 134 (Supplement_1): 2666.

https://doi.org/10.1182/blood-2019-132030

Published: 2019

Journal Articles

Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia

Shruti Bhatt, PhD, Marissa Pioso, Elyse Ann Olesinski, Binyam Yilma, Leutz Buon, Sophia Adamia, PhD, Holly Zhu, Jeremy Ryan, Youzhen Wang, Morris Erick, Ensar Halilovic, David M. Weinstock, MD, Jacqueline S Garcia, MD, Anthony Letai

Blood (2019) 134 (Supplement_1): 2551.

https://doi.org/10.1182/blood-2019-131101

Published: 2019

Journal Articles

DNA Damage Repair Interference By WEE1 Inhibition with AZD1775 Overcomes Combined Azacitidine and Venetoclax Resistance in Acute Myeloid Leukmeia (AML)

Raoul Tibes, MD PhD, Diego Ferreira Coutinho, PhD, Michael Tuen Tuen, Xufeng Chen, PhD, Christina Glytsou, Ioannis Aifantis, Sergey Shmelkov, MD

Blood (2019) 134 (Supplement_1): 2559.

https://doi.org/10.1182/blood-2019-130931

Published: 2019

Journal Articles

Anti-Apoptotic BCL-2 Family Members Confer Resistance to Calicheamicin-Based Antibody-Drug Conjugate Therapy of Acute Leukemia

Colin D. Godwin, MDMPhil, Olivia M. Bates, BA, Sae Rin Jean, PhD, George S. Laszlo, PhD, Eliotte E. Garling, BA, Mary E. Beddoe, BS, Michael H. Cardone, PhD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 2561.

https://doi.org/10.1182/blood-2019-126110

Published: 2019

Journal Articles

IGF1R-IRS1/2 Signaling Pathway Is a Potential Target for FLT3-Mutated Acute Myeloid Leukemia

Juan L Coelho-Silva, BSc, MSc, Diego A Pereira-Martins, MSc, Virginia Campos Silvestrini, BSc, MSc, Eduardo M Rego, MD PhD, Vitor Marcel Faca, PhD, João Agostinho Machado-Neto, PhD, Fabiola Traina, MD PhD

Blood (2019) 134 (Supplement_1): 2689.

https://doi.org/10.1182/blood-2019-132129

Published: 2019

Journal Articles

CD3xCD19 Dart Treatment Is Efficient in Venetoclax Resistant CLL and Reverses T Cell Dysfunction

Anne W. J. Martens, MSc, Susanne R. Janssen, MSc, Ingrid A.M. Derks, Sanne Tonino, MD PhD, Eric Eldering, Gerritje J. W. van der Windt, Arnon P. Kater, MD PhD

Blood (2019) 134 (Supplement_1): 3043.

https://doi.org/10.1182/blood-2019-123350

Published: 2019

Journal Articles

Efficacy of Targeted Therapy in Novel Pre-Clinical in Vitro and In Vivo Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL)

Vrajesh Karkhanis, PhD, Warren Fiskus, BSc,PhD, Christopher Peter Mill, PhD BA, Abhishek Maiti, MBBS, Bernardo H Lara, James V Maher, Isean Bhalla, Nancy Shao, Michael R Green, PhD, Joseph D. Khoury, MD, Kapil N. Bhalla, MD

Blood (2019) 134 (Supplement_1): 3961.

https://doi.org/10.1182/blood-2019-132041

Published: 2019

NARROW

MCL-1 and BCL-XL: blood brothers

Requirement for antiapoptotic MCL-1 during early erythropoiesis

IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia

Characterization of Mechanisms of Acquired Venetoclax-Insensitivity in B-Cell Precursor Acute Lymphoblastic Leukemia

Rive-CLL: Phase 1 Trial of Rituximab, Idelalisib, and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Ibrutinib Therapy Downregulates Toso, the Fcr for IgM, Expression in CLL Patients

Cross-Talk between Cytokine and NF-ĸb Signaling in the CLL Microenvironment Can Affect Sensitivity for Venetoclax

First Description of B Cell Maturation Antigen Expression in Light Chain Amyloidosis

The Effect of Apoptosis Inhibitor Blockade Agents on the Third Generation CD19 CAR T Cells

Targeting CD38 high Acute Myeloid Leukaemia with "Affinity Optimized" Chimeric Antigen Receptor and Membrane Bound TRAIL Expressing Natural Killer Cells

Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL

Identification of a New Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia and Studies on Its Mechanism of Action

A Novel BCL-2/BCL-Xl Dual Inhibitor Overcomes Ibrutinib-Resistance Conferred By the Upregulation of Integrin Pathway and BCL-Xl

The Splicing Modulator GEX1A Exhibits Potent Anti-Leukemic Activity Both in Vitro and In Vivo through Inducing an MCL1 Splice-Switch in Pre-Clinical Models of Acute Myeloid Leukemia

Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia

DNA Damage Repair Interference By WEE1 Inhibition with AZD1775 Overcomes Combined Azacitidine and Venetoclax Resistance in Acute Myeloid Leukmeia (AML)

Anti-Apoptotic BCL-2 Family Members Confer Resistance to Calicheamicin-Based Antibody-Drug Conjugate Therapy of Acute Leukemia

IGF1R-IRS1/2 Signaling Pathway Is a Potential Target for FLT3-Mutated Acute Myeloid Leukemia

CD3xCD19 Dart Treatment Is Efficient in Venetoclax Resistant CLL and Reverses T Cell Dysfunction

Efficacy of Targeted Therapy in Novel Pre-Clinical in Vitro and In Vivo Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only